# A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma

> **NCT04502862** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 202 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** SAR231893
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04502862
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-10
- **Primary completion:** 2023-10-03
- **Final completion:** 2023-11-10
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2024-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04502862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04502862, "A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04502862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*